Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Triple Negative Breast Neoplasms 1Small Cell Lung Cancer Extensive Stage 1Pathologic Complete Response 1Oesophagogastric Cancer 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell, Marginal Zone 1HR+/HER2- Breast Cancer 1Congenital Abnormalities 1Breast Neoplasms 1

Interventions

Epirubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × HR+/HER2- Breast Cancer × Epirubicin × Clear all
NCT06860529 2025-06-23

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Henan Cancer Hospital

Phase 2 Recruiting
357 enrolled
Breast

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡